Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.22.2
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Nov. 30, 2019
Jan. 31, 2018
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized         $ 6,276 $ 5,162 $ 11,743 $ 9,989    
Deferred revenue         3,591   3,591   $ 10,181  
Global Blood Therapeutics                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue         3,365   3,365   8,913  
Global Blood Therapeutics | Collaboration Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Initial period of research term 3 years                  
Additional extension period for research term upon mutual agreement 1 year                  
Upfront payment receivable $ 20,000                  
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses $ 40,000                  
Agreement termination, prior written notice if notice delivered during the research term 9 months                  
Agreement termination, prior written notice if notice delivered after the expiration or termination of the research term 90 days                  
Total transaction price $ 60,000           50,000   54,200 $ 60,000
Upfront non-refundable and non-creditable payment 20,000                  
Reimbursable costs $ 40,000                  
Revenue recognized         5,700 3,300 10,700 7,400    
Deferred revenue         3,400   3,400      
Global Blood Therapeutics | Collaboration Agreement | Maximum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Period of extension of initial research term 2 years                  
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting $ 315,000                  
Incyte                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized         600 $ 1,900 1,000 $ 2,600    
Deferred revenue         $ 226   226   $ 1,268  
Incyte | Stock Purchase Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Aggregate purchase price       $ 10,000            
Shares issued       793,021            
Share price (in dollars per share)       $ 12.61            
Premium to volume-weighted sale price of shares (as a percent)       30.00%            
Trading days within which the purchase price represents a thirty percent (30%) premium to the volume-weighted sale price of the shares       15 days            
Incyte | Collaboration Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total transaction price   $ 12,300 $ 12,800       12,800      
Upfront non-refundable and non-creditable payment             2,500      
Up-front consideration       $ 10,000            
Up-front consideration, cash       2,500            
Up-front consideration, pre-paid research funding       $ 7,500            
Prepaid research amount             7,500      
Premium paid on equity investment             2,300      
Collaboration agreement additional consideration incurred             $ 500